JP2007538024A5 - - Google Patents

Download PDF

Info

Publication number
JP2007538024A5
JP2007538024A5 JP2007517041A JP2007517041A JP2007538024A5 JP 2007538024 A5 JP2007538024 A5 JP 2007538024A5 JP 2007517041 A JP2007517041 A JP 2007517041A JP 2007517041 A JP2007517041 A JP 2007517041A JP 2007538024 A5 JP2007538024 A5 JP 2007538024A5
Authority
JP
Japan
Prior art keywords
group
alkyl
phenyl
cycloalkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007517041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/005229 external-priority patent/WO2005110422A2/en
Publication of JP2007538024A publication Critical patent/JP2007538024A/ja
Publication of JP2007538024A5 publication Critical patent/JP2007538024A5/ja
Pending legal-status Critical Current

Links

JP2007517041A 2004-05-19 2005-05-13 アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物 Pending JP2007538024A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011894 2004-05-19
PCT/EP2005/005229 WO2005110422A2 (en) 2004-05-19 2005-05-13 Treatment of diseases associated with altered level of amyloid beta peptides

Publications (2)

Publication Number Publication Date
JP2007538024A JP2007538024A (ja) 2007-12-27
JP2007538024A5 true JP2007538024A5 (enExample) 2008-07-03

Family

ID=34979633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517041A Pending JP2007538024A (ja) 2004-05-19 2005-05-13 アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物

Country Status (5)

Country Link
US (4) US7393843B2 (enExample)
EP (1) EP1750719A2 (enExample)
JP (1) JP2007538024A (enExample)
CA (1) CA2567223A1 (enExample)
WO (1) WO2005110422A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1866034A1 (en) * 2005-03-30 2007-12-19 Boehringer Ingelheim International GmbH Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
US20100298278A1 (en) * 2005-08-11 2010-11-25 Christian Eickmeier Inhibitors of beta-secretase for the treatment of alzheimer's disease
JP2009504612A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
AR066151A1 (es) 2007-06-01 2009-07-29 Schering Corp Moduladores de gama secretasa
EP2152695A2 (en) 2007-06-01 2010-02-17 Schering Corporation Gamma secretase modulators
PE20090957A1 (es) * 2007-08-06 2009-07-13 Schering Corp Moduladores de gamma secretasa
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
CA2708300A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
AU2009314049B2 (en) 2008-11-13 2015-03-05 Merck Sharp & Dohme Corp. Gamma secretase modulators
CA2742472A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
EP2379566A2 (en) 2008-12-22 2011-10-26 Schering Corporation Gamma secretase modulators
US20100233156A1 (en) * 2009-03-09 2010-09-16 Georgetown University Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
WO2010107435A1 (en) * 2009-03-19 2010-09-23 Bristol-Myers Squibb Company A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443118A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2012125720A2 (en) 2011-03-14 2012-09-20 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
WO2017004168A1 (en) 2015-06-29 2017-01-05 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant
CN118791377B (zh) * 2024-09-10 2025-02-07 山东国邦药业有限公司 一种2,4,5-三氟苯乙酸的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674876A (en) 1969-06-09 1972-07-04 Pfizer Benzothiazine dioxides as lipid regulating agents
US3998954A (en) * 1971-02-05 1976-12-21 Pfizer Inc. 1,3(2H,4H)-Dioxoisoquinoline-4-carboxamides used as anti-inflammatory agents
US3891637A (en) 1974-10-01 1975-06-24 Pfizer Process for the production of carboxamides of oxo-1,2-benzothiazine-1,1-dioxides
MC1135A1 (fr) 1976-02-23 1977-11-18 Hoffmann La Roche Derives de thiazine
US4175085A (en) 1976-02-23 1979-11-20 Hoffmann-La Roche Inc. Thienothiazine derivatives
LU78009A1 (de) 1977-08-22 1979-05-23 Hoffmann La Roche Verfahren zur herstellung von thiazinderivaten
US4683306A (en) 1984-07-13 1987-07-28 Yuhan Corporation Co., Ltd. Process for the preparation of 3,4-dihydro-2-substituted-2H-1,2-thiazine-carboxylic acid 1,1-dioxide derivatives
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992013069A1 (en) 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
JPH05286941A (ja) * 1991-09-30 1993-11-02 Nippon Zeon Co Ltd ピリジン−2,6−ジオン誘導体
DK0620849T3 (da) * 1992-01-07 2003-10-20 Elan Pharm Inc Transgene dyremodeller for Alzheimer's sygdom
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
WO1995011968A1 (en) 1993-10-27 1995-05-04 Athena Neurosciences, Inc. Transgenic animals harboring app allele having swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DK1493439T3 (da) * 1997-04-02 2012-01-30 Brigham & Womens Hospital Middel til fastlæggelse af en persons risikoprofil for aterosklerotisk sygdom
JP2003505359A (ja) 1999-07-16 2003-02-12 レオ・ファーマ・アクティーゼルスカブ 新規アミノベンゾフェノン
AU782386C (en) * 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
WO2001078721A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
CN1613012A (zh) * 2001-11-05 2005-05-04 布赖汉姆妇女医院 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记
WO2003088811A2 (en) * 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases

Similar Documents

Publication Publication Date Title
JP2007538024A5 (enExample)
JP2010523476A5 (enExample)
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2006524660A5 (enExample)
JP2011509309A5 (enExample)
JP2013508279A5 (enExample)
JP2006517591A5 (enExample)
JP2007519649A5 (enExample)
JP2014511891A5 (enExample)
JP2005539088A5 (enExample)
JP2014530900A5 (enExample)
JP2011516511A5 (enExample)
JP2010523522A5 (enExample)
JP2008539267A5 (enExample)
JP2004516314A5 (enExample)
JP2012533546A5 (enExample)
JP2008539268A5 (enExample)
JP2016040288A5 (enExample)
JP2007508360A5 (enExample)
JP2013531070A5 (enExample)
JP2017517538A5 (enExample)
JP2007507494A5 (enExample)
JP2019520344A5 (enExample)
JP2020505354A5 (enExample)